TriSalus Life Sciences, Inc.
Datakwaliteit: 100%
€ 4,49
€ 0,00
(0,00%)
6 months return
—
Momentum
Neutral
Net margin
-86,88%
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)53,41%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROIC-73,98%
Net Margin-86,88%
Op. Margin-59,68%
Veiligheid
Debt / Equity
N/A
Current Ratio3,05
Interest Coverage-4,86
Waardering
PE (TTM|NTM)
-6,65 | -17,96
Onder sectorgemiddelde (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Negative free cash flow of -18,93 M
Capital efficient — spends only 2,03% of revenue on capex
Price History
Financiële Trends
Koersdoel Analisten
5 analisten
Buy
+104.9%
upside to target
Huidig
€ 4,49
Consensus Target
€ 9,20
€ 7,00
Laag
€ 11,00
Hoog
Vooruitzicht
Forward K/W
-17,96
Forward WPA
-€ 0,25
Omzet Sch.
80,81 M
Winstverassingen
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -€ 0,16
·
Rev Est: 10,44 M
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | -€ 0,27 | -€ 0,23 | -€ 0,87 | -€ 0,05 | — | — |
| Estimate | -€ 0,20 | -€ 0,22 | -€ 0,17 | -€ 0,13 | -€ 0,16 | -€ 0,11 |
| Verrassing | -34,74% | -2,80% | -425,70% | +61,46% | — | — |
Growth
Rev 5Y: N/A · Earnings 1Y: N/A
Growth
Rev 5Y: N/A · Earnings 1Y: N/A| Revenue Growth (1Y) | 53,41% | Revenue Growth (3Y) | 56,18% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
Profitability
ROE: N/A · Net Margin: -86,88%
Profitability
ROE: N/A · Net Margin: -86,88%| Revenue (TTM) | 45,15 M | Net Income (TTM) | -39,23 M |
| ROE | N/A | ROA | -100,87% |
| Gross Margin | 84,57% | Operating Margin | -59,68% |
| Net Margin | -86,88% | Free Cash Flow (TTM) | -18,93 M |
| ROIC | -73,98% | FCF Growth (3Y) | N/A |
Safety
D/E: N/A · Current: 3,05
Safety
D/E: N/A · Current: 3,05| Debt / Equity | N/A | Current Ratio | 3,05 |
| Interest Coverage | -4,86 | Asset Turnover | 1,16 |
| Working Capital | 22,42 M | Tangible Book Value | -26,73 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: -6,65 · EV/EBITDA: N/A
Valuation
P/E: -6,65 · EV/EBITDA: N/A| P/E Ratio | -6,65 | Forward P/E | -17,96 |
| P/B Ratio | N/A | P/S Ratio | 5,78 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 3,23 | Fwd Earnings Yield | N/A |
| FCF Yield | -7,25% | ||
| Market Cap | 261,01 M | Enterprise Value | 271,09 M |
Per Share
EPS: -1,84 · FCF/Share: -0,31
Per Share
EPS: -1,84 · FCF/Share: -0,31| EPS (Diluted TTM) | -1,84 | Revenue / Share | 0,74 |
| FCF / Share | -0,31 | OCF / Share | -0,29 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 48,26% · CapEx/Rev: 2,03%
Efficiency
FCF Conv: 48,26% · CapEx/Rev: 2,03%| CapEx / Revenue | 2,03% | FCF Conversion | 48,26% |
| SBC-Adj. FCF | -27,25 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 45,15 M | 29,43 M | 18,51 M | — | — |
| Net Income | -39,23 M | -30,05 M | -59,04 M | 5,54 M | 4,77 M |
| EPS (Diluted) | -1,84 | -1,31 | -6,73 | — | — |
| Gross Profit | 38,19 M | 25,33 M | 15,91 M | — | — |
| Operating Income | -26,95 M | -36,17 M | -54,15 M | -2,75 M | -3,04 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 14,97 M | 17,69 M | 29,51 M | — | — |
| SG&A Expenses | — | — | — | — | — |
| D&A | 626.000,0 | 744.000,0 | 702.000,0 | — | — |
| Interest Expense | 5,54 M | 3,09 M | 16.000,0 | — | — |
| Income Tax | 7.000,0 | 6.000,0 | 9.000,0 | 570.854,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 35,33 M | 23,97 M | 25,73 M | 20,19 M | 252,01 M |
| Total Liabilities | 69,19 M | 49,87 M | 51,66 M | 13,65 M | 23,50 M |
| Shareholders' Equity | -33,86 M | -25,89 M | -25,94 M | -13,27 M | -21,48 M |
| Total Debt | 33,05 M | 22,08 M | — | — | — |
| Cash & Equivalents | 20,44 M | 8,53 M | 11,78 M | 153.563,0 | 1,33 M |
| Current Assets | 32,24 M | 20,67 M | 20,86 M | 359.892,0 | 2,01 M |
| Current Liabilities | 11,50 M | 10,23 M | 14,69 M | 2,50 M | — |
Sectorvergelijking
vs Manufacturing sector mediaan (1605 peers)
Vergeleken met vergelijkbare bedrijven in Manufacturing
Sectorvergelijking
vs Manufacturing sector mediaan (1605 peers) Vergeleken met vergelijkbare bedrijven in Manufacturing| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -6,7 | -1,5 |
| P/B | — | 1,6 |
| ROE % | — | -54,7 |
| Net Margin % | -86,9 | -41,5 |
| Rev Growth 5Y % | — | 1,7 |
| D/E | — | 0,3 |
{"event":"ticker_viewed","properties":{"ticker":"TLSI","listing_kind":"stock","pathname":"/stocks/tlsi","exchange":"NASDAQ","country":"US"}}